Patents by Inventor Hongxia Ding

Hongxia Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of icaritin for the preparation of composition for treating cancer
    Patent number: 9301942
    Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 5, 2016
    Assignee: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Kun Meng, Hongxia Ding, Shu Li, Ya Tuo, Yueqiu Shen
  • Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects
    Patent number: 9221781
    Abstract: The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-?36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: December 29, 2015
    Assignee: BEIJING SHENOGEN PHARAM GROUP LTD.
    Inventors: Kun Meng, Hongxia Ding, Jin Li
  • Benzopyrone estrogen receptor regulator
    Patent number: 9090583
    Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 28, 2015
    Assignee: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Kun Meng, Jin Li
  • SYNTHESIS OF POLYHYDROXY CHROMENONE COMPOUNDS AND THEIR ANTI-TUMOR EFFECTS
    Publication number: 20150011618
    Abstract: The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-?36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.
    Type: Application
    Filed: December 31, 2012
    Publication date: January 8, 2015
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Jin Li, Kun Meng
  • USE OF ICARITIN FOR THE PREPARATION OF COMPOSITION FOR TREATING CANCER
    Publication number: 20140357876
    Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Kun MENG, Hongxia DING, Shu LI, Ya TUO, Yueqiu SHEN
  • BENZOPYRONE ESTROGEN RECEPTOR REGULATOR
    Publication number: 20130303544
    Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
    Type: Application
    Filed: December 21, 2011
    Publication date: November 14, 2013
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Kun Meng, Jin Li